Mills GB - Search Results

1

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Liu JF, et al. Among authors: mills gb. Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573169 Free PMC article.

2

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr. Xu FJ, et al. Among authors: mills gb. Clin Cancer Res. 1997 Sep;3(9):1629-34. Clin Cancer Res. 1997. PMID: 9815853

3

Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells.

Frankel A, Mills GB. Frankel A, et al. Among authors: mills gb. Clin Cancer Res. 1996 Aug;2(8):1307-13. Clin Cancer Res. 1996. PMID: 9816301

4

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Hagopian GS, et al. Among authors: mills gb. Clin Cancer Res. 1999 Mar;5(3):655-63. Clin Cancer Res. 1999. PMID: 10100719

5

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.

Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr. Xu F, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3653-60. Clin Cancer Res. 1999. PMID: 10589783

6

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC Jr, Mills GB. Pustilnik TB, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3704-10. Clin Cancer Res. 1999. PMID: 10589790

7

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.

Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC Jr, Mills GB, Silva EG. Gershenson DM, et al. Among authors: mills gb. Clin Cancer Res. 1999 Dec;5(12):4053-8. Clin Cancer Res. 1999. PMID: 10632339

8

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Furui T, et al. Among authors: mills gb. Clin Cancer Res. 1999 Dec;5(12):4308-18. Clin Cancer Res. 1999. PMID: 10632375

9

Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.

Ramondetta L, Mills GB, Burke TW, Wolf JK. Ramondetta L, et al. Among authors: mills gb. Clin Cancer Res. 2000 Jan;6(1):278-84. Clin Cancer Res. 2000. PMID: 10656459

10

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. Hu L, et al. Among authors: mills gb. Clin Cancer Res. 2000 Mar;6(3):880-6. Clin Cancer Res. 2000. PMID: 10741711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,149 results

Search Page

Filters